Renata Limited is an Indian pharmaceutical company headquartered in Mumbai, Maharashtra. It is a publicly traded entity listed on the National Stock Exchange of India (NSE) and the Bombay Stock Exchange (BSE) under the ticker symbol “RENATA.” The company operates as a subsidiary of the Renata Group, a diversified business conglomerate with interests in pharmaceuticals, health care, and related sectors.
Overview
Renata Limited manufactures, markets, and distributes a range of pharmaceutical products, including over‑the‑counter (OTC) medicines, prescription drugs, nutraceuticals, and consumer health items. The company’s product portfolio covers therapeutic areas such as cardiology, gastroenterology, pain management, dermatology, and anti‑infectives.
History
Renata Limited traces its origins to the establishment of the Renata Group in the early 1970s. The pharmaceutical subsidiary was formally incorporated in the mid‑1990s, consolidating the group’s drug‑manufacturing activities under a single corporate entity. Since its inception, Renata has expanded its manufacturing capacity through the development of multiple GMP‑certified plants across India.
Operations and Facilities
The company operates several manufacturing facilities located in Maharashtra and other Indian states. These plants are equipped to produce solid dosage forms, liquids, and nutraceutical products and are compliant with international quality standards. Renata Limited also maintains a network of sales and distribution offices in India and export hubs in more than 50 countries, facilitating a global market presence.
Product Portfolio
Renata’s product range includes branded OTC medications such as analgesics, antacids, and dietary supplements, as well as prescription pharmaceuticals covering chronic and acute conditions. The company emphasizes research and development (R&D) to introduce new formulations and to expand its therapeutic offerings.
Financial and Market Position
As a publicly listed company, Renata Limited files regular financial statements with Indian regulatory authorities. The firm reports revenue in the multi‑billion‑rupee range and distinguishes itself as a mid‑size player within the Indian pharmaceutical sector, competing with both domestic and multinational firms.
Regulatory and Quality Compliance
Renata Limited’s manufacturing sites are approved by the Central Drugs Standard Control Organization (CDSCO) of India and have obtained certifications from international regulatory bodies, enabling the export of its products to regulated markets.
Corporate Governance
The company is governed by a board of directors and adheres to corporate governance standards applicable to listed entities in India. Its leadership team includes professionals with experience in pharmaceuticals, finance, and international business.
References
- Renata Limited official website (corporate and investor sections)
- Listings on the National Stock Exchange of India and Bombay Stock Exchange
- Publicly available regulatory filings and annual reports submitted to the Ministry of Corporate Affairs, Government of India.